The meta-analysis combining data from the independent data sets assessed, showed that ANXA2 lies within the 1%–16% of the most consistently underexpressed genes for prostate adenocarcinoma versus normal prostate gland. Here, ANXA2 is linked to prostate adenocarcinoma.